Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Roche Suspends Phase II Mircera Study In Chemo-Induced Anemia

This article was originally published in The Pink Sheet Daily

Executive Summary

Firm halts recruitment of anemic non-small cell lung cancer patients due to an “imbalance” of deaths across study arms but maintains they are not related to the drug.

You may also be interested in...



Boxed Warning In Development For Procrit, Aranesp

Erythropoietin marketers J&J and Amgen will participate in an FDA Oncologic Drugs Advisory Committee meeting in May.

Boxed Warning In Development For Procrit, Aranesp

Erythropoietin marketers J&J and Amgen will participate in an FDA Oncologic Drugs Advisory Committee meeting in May.

Amgen “Dear Doctor” Letter Warns Of Risk Of Death Associated With Aranesp

Letter follows release of data in patients receiving darbepoetin alfa who have anemia that is not due to concurrent chemotherapy, an off-label use.

Related Content

Topics

UsernamePublicRestriction

Register

PS065676

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel